Abstract

Introduction

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Conventional therapies covering either chemotherapy or combination therapy still have sub-optimal responses with significant adverse effects and toxicity. Moreover, tumor cells usually acquire resistance quickly for traditional approaches, limiting their use in HCC. Interest in nanomedicine due to minimal systemic toxicity and a high degree of target-specific drug-delivery have pulled the attention of health scientists in this area of therapeutics.

Area covered

The review covers the incidence and epidemiology of HCC, proposed molecular drug targets, mechanistic approach and emergence of nanomedicines including nanoparticles, lipidic nanoparticles, vesicular based nanocarrier, virus-like particles with momentous therapeutic aspects including biocompatibility, and toxicity of nanocarriers along with conclusions and future perspective, with efficient approach to safely cross physiological barriers to reach the target site for treating liver cancer.

Expert opinion

Remarkable outcomes have recently been observed for the therapeutic efficacy of nanocarriers with respect to a specific drug target against the treatment of HCC by existing under trial drugs.

中文翻译：

---

肝细胞癌靶向纳米颗粒和纳米药物的现状和未来方向

摘要

介绍

肝细胞癌（HCC）是世界范围内的主要健康问题。涵盖化学疗法或联合疗法的常规疗法仍存在次优反应，并具有明显的不良反应和毒性。而且，肿瘤细胞通常对于传统方法迅速获得耐药性，从而限制了它们在肝癌中的使用。由于最小的全身毒性和高度的靶标特异性药物递送，人们对纳米医学的兴趣吸引了健康科学家在治疗领域的关注。

覆盖面积

综述涵盖了HCC的发病率和流行病学，拟议的分子药物靶标，机制性方法以及包括纳米颗粒，脂质纳米颗粒，囊泡基纳米载体，具有重大治疗意义的病毒样颗粒的纳米药物的出现，包括生物相容性和纳米载体的毒性，以及结论和结论。未来的前景，以有效的方法安全地越过生理障碍到达治疗肝癌的目标部位。

专家意见

最近已经观察到纳米载体相对于针对特定药物靶标的针对现有治疗药物治疗HCC的治疗效果显着。